Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transformation and the company’s relevance in 2017. Mackie, who joined the business two years ago, outlines Ergomed’s risk-sharing business model and sheds light on how partnerships are made between the company and its biotech and pharma counterparts. Headquartered in London, UK, Ergomed is seeking co-development deals particularly in oncology, neurology and orphan diseases. The company currently has collaborations with Grupo Ferrer for lorediplon, an orally available non-benzodiazepine inhibitor of the gamma-aminobutyric acid A that is in development as a treatment for insomnia; Aeterna Zentaris for the development of AEZS 108 in endometrial cancer; Modus for sevuparin sodium as a treatment for patients with sickle cell disease; and others.
Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Andrew Mackie – CBO, Ergomed